LB-102 is under clinical development by LB Pharmaceuticals and currently in Phase II for Schizophrenia. According to GlobalData, Phase II drugs for Schizophrenia have a 44% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how LB-102’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

LB-102 overview

LB-102 is under development for the treatment of schizophrenia and depression. The drug candidate is a N-methylated analogue of amisulpride (a racemic compound). It is administered through oral route ad formulated capsule. It acts by targeting dopamine receptors (D2 and D3) and 5-hydroxytryptamine receptor 7 (5 HT7) receptor.

LB Pharmaceuticals overview

LB Pharmaceuticals (LB Pharma) is a drug development company that specialized in the areas of schizophrenia and antipsychotic. The company is headquartered in New York City, the US.

For a complete picture of LB-102’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.